Marketed under the brand name DGJAJ, it helps in the faster recovery of hospitalised patients and reduces supplemental oxygen dependence
Hetero’s drug is a biosimilar version of Roche’s Actemra/RoActemra and will be available at the end of this month
The bioequivalence study was conducted by Accutest Research India, one of the preferred CRO players in India
The newest entrant from the company is the MOSS 1800F with an oxygen flow rate of 180 LPM or 10.8 Nm3/hour
The transactions resulted in a net cash inflow of Rs 183 crores for HCG in addition to the take-over of the labs and clinical research business
At present 18 per cent of the local pharmaceutical market is under government's price control
The trial will be conducted across eight sites in Maharashtra
Implementation of the system to provide faster, seamless and hassle-free healthcare solutions
The trial will be conducted across 10 sites in India
This is Omeza’s first Rx product and the first drug/device combination matrix of its kind for chronic wound care
Subscribe To Our Newsletter & Stay Updated
